Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1

Ou, W; Ye, S; Yang, W; Wang, Y; Ma, Q; Yu, C; Shi, H; Yuan, Z; Zhong, G; Ren, J; Zhu, W; Wei, Y
July 2012
Cancer Gene Therapy;Jul2012, Vol. 19 Issue 7, p489
Academic Journal
LKB1 is a novel candidate tumor suppressor gene in lung cancer. In this study, we evaluated the effect of cationic liposomes (LPs)-mediated LKB1 gene (LPs-pVAX-LKB1) on low-dose cisplatin (cis-diamminedichloroplatinum)-mediated antitumor activity in lung cancer, both in vitro and in vivo. Our study demonstrated that cationic LPs-mediated LKB1 gene therapy could sensitize the response of lung cancer cells to cisplatin, and significantly induce apoptosis and inhibit proliferation, invasion and metastasis, compared with control groups. Combined treatment with intratumoral administration of Lps-pVAX-LKB1 and intraperitoneal injection of low-dose cisplatin into subcutaneous A549 lung tumor xenograft resulted in significant (P<0.01) inhibition of tumor growth. Furthermore, combined treatment with intravenous injections of Lps-pVAX-LKB1 and intraperitoneal injection of low-dose cisplatin into mice bearing experimental A549 lung metastasis demonstrated significant (P<0.01) decrease in the number of lung metastatic tumor nodules. Mice life spans of combination treatment group were also dramatically prolonged, compared with controls. Further studies indicated that LKB1-enhancing cisplatin-mediated antitumor effects might be associated with the upregulation of p-p53 and p-JNK, and downregulation of p-mammalian target of rapamycin, matrix metalloproteinase (MMP)-2 and MMP-9. This study suggests that the combination of LKB1 gene therapy with low-dose cisplatin-based chemotherapy may be a potent therapeutic strategy for lung cancer.


Related Articles

  • Cisplatin induced paroxysmal supraventricular tachycardia. Raja, Waseem; Mir, M. Hussain; Dar, Imtiyaz; Banday, Muzamil Ahmad; Ahmad, Irfan // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2013, Vol. 34 Issue 4, p330 

    Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of platinum-containing anti-cancer drugs that act by binding to and causing cross-linking of deoxyribonucleic acid, which ultimately triggers apoptosis. Cisplatin has a broadspectrum antineoplastic activity against...

  • Gefitinib inferior to placebo in patients with stage III non-small cell lung cancer.  // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p9 

    The article discusses research being done on the use of gefitinib in patients with stage III non-small cell lung cancer. It references a study by K. Kelly, K. Chansky, L. E. Gasper and colleagues, published in the 2008 issue of the "Journal of Clinical Oncology." It was discovered by researchers...

  • Study on Invadopodia Formation for Lung Carcinoma Invasion with a Microfluidic 3D Culture Device. Wang, Shanshan; Li, Encheng; Gao, Yanghui; Wang, Yan; Guo, Zhe; He, Jiarui; Zhang, Jianing; Gao, Zhancheng; Wang, Qi // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Invadopodia or invasive feet, which are actin-rich membrane protrusions with matrix degradation activity formed by invasive cancer cells, are a key determinant in the malignant invasive progression of tumors and represent an important target for cancer therapies. In this work, we presented a...

  • Efficacy of Cisplatin and Vinorelbine in Patients with Metastatic Non-Small Cell Lung Carcinoma. Yımaz, Ufuk; Halilçolar, Huseyin; Yıldırım, Yasemin; Yapıcıoğlu, Sena; Ünsal, İpek; Mahleç, Ceyda // Turk Toraks Dergisi / Turkish Thoracic Journal;Dec2008, Vol. 9 Issue 4, p137 

    Introduction: Cisplatin-based chemotherapy improved survival and quality of life in lung cancer. The aim of this study is to evaluate the feasibility of the cisplatin-vinorelbine (day 1+8) in patients with metastatic NSCLC. Material and Method: ECOG performance 0-1, chemotherapy-naive stage IV...

  • Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2. Shimin Pei; Xu Yang; Huanan Wang; Hong Zhang; Bin Zhou; Di Zhang; Degui Lin; Pei, Shimin; Yang, Xu; Wang, Huanan; Zhang, Hong; Zhou, Bin; Zhang, Di; Lin, Degui // BMC Cancer;12/16/2015, Vol. 15, p1 

    Background: Metastasis is the major cause of death in breast cancers. MMPs play a key role in tumor microenvironment that facilitates metastasis. The existing researches suggest that the high expression of gelatinase A and B (MMP2 and MMP9) promote the metastasis of breast cancer....

  • Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Youlyouz-Marfak, I.; Gachard, N.; Le Clorennec, C.; Najjar, I.; Baran-Marszak, F.; Reminieras, L.; May, E.; Bornkamm, G. W.; Fagard, R.; Feuillard, J. // Cell Death & Differentiation;Feb2008, Vol. 15 Issue 2, p376 

    Chemotherapeutic drugs such as fludarabine*, doxorubicin or cisplatin are very potent activators of the anti-oncogene p53. Convergent studies suggest that p53 and STAT1 (signal transducer and activator of transcription 1) cooperate in the induction of cell death. We show that these drugs are...

  • Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer—An Old Rivalry Renewed. Azzoli, Christopher G.; Kris, Mark G.; Pfister, David G. // JNCI: Journal of the National Cancer Institute;6/6/2007, Vol. 99 Issue 11, p828 

    The article presents a study concerning the efficacy of cisplatin and carboplatin in treating metastatic non-small-cell lung cancer (NSCLC). Carboplatin is a chemotherapy drug used against some forms of cancer such as ovarian carcinoma, lung, head and neck cancers. The authors cite clinical...

  • Cisplatin + pemetrexed as first-line therapy for advanced NSCLC.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p5 

    The article discusses research on the use of combined cisplatin and pemetrexed for advanced nonsquamous non-small cell lung cancer (NSCLC). It references the study "Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer," by R....

  • NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway. Chen, Tian-Jun; Zhou, Yue-Fei; Ning, Jie-Juan; Yang, Tian; Ren, Hui; Li, Yang; Zhang, Shuo; Chen, Ming-Wei // Cellular Physiology & Biochemistry (Karger AG);Jun2015, Vol. 36 Issue 3, p893 

    Background: Drug combination therapies using cisplatin and natural products are common practice in the treatment of human lung cancer. Osthole is a natural compound extracted from a number of medicinal plants and has been shown to exert strong anticancer activities with low toxicity. Methods: In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics